Intermountain Healthcare

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 Recursion Pharmaceuticals is a biotechnology company that combines experimental biology and AI to identify treatments for rare diseases, aging, inflammation, infectious diseases, and immunology. The company's approach is based on experimenting by making healthy cells sick, scanning images, and experimenting with its AI platform to understand how they differ from healthy cells. Its lab can perform one million such experiments a week.
 
 
 Recursion operates as a full-stack player engaged in drug discovery and development. It has seven drug candidates focused on rare diseases and oncology, five of which are in Phase II or advancing toward Phase III.
 
 
 In 
 <a href="https://www.globenewswire.com/news-release/2023/05/08/2663211/0/en/Recursion-Enters-into-Agreements-to-Acquire-Cyclica-and-Valence-to-Bolster-Chemistry-and-Generative-AI-Capabilities.html">
 May 2023
 </a>
 , Recursion acquired two drug discovery companies, Cyclica (for USD 40 million) and Valence (USD 47.5 million), to strengthen its chemistry and GenAI capabilities. In 
 <a href="https://www.businesswire.com/news/home/20160425005113/en/Recursion-Pharmaceuticals-Announces-Research-Agreement-With-Sanofi-Genzyme#:~:text=Recursion%20announces%20a%20research%20agreement,across%20dozens%20of%20genetic%20diseases.">
 June 2023
 </a>
 , the company also launched its Canadian headquarters in Toronto.
 
 
 Key customers and partnerships
 
 
 The company was also engaged in Big Pharma collaborations in more competitive areas. Some of these were: 
 <a href="https://www.bayer.com/media/en-us/bayer-collaborates-with-recursion-to-strengthen-digital-drug-discovery-and-advance-new-therapies-for-fibrotic-diseases/">
 Bayer
 </a>
 (September 2020) to develop novel treatments for fibrotic diseases, which shifted focus to precision oncology treatments in 
 <a href="https://www.bayer.com/media/en-us/bayer-and-recursion-focus-research-collaboration-on-oncology/">
 November 2023
 </a>
 ; NVIDIA (July 2023) to leverage 
 <a href="https://sp-edge.com/updates/20069">
 NVIDIA&rsquo;
 </a>
 s cloud services; 
 <a href="https://www.biospace.com/article/recursion-partners-with-roche-to-develop-up-to-40-assets-in-neuroscience-and-oncology/">
 Roche
 </a>
 (December 2021) to develop 40 new treatments for neuroscience and oncology targets; 
 <a href="https://www.recursion.com/news/rec-4881">
 Takeda Pharmaceutical
 </a>
 (May 2020) to obtain the license to Takeda&rsquo;s MEK inhibitor, TAK-733, and develop it for the treatment of a hereditary cancer syndrome; and 
 <a href="https://www.businesswire.com/news/home/20160425005113/en/Recursion-Pharmaceuticals-Announces-Research-Agreement-With-Sanofi-Genzyme#:~:text=Recursion%20announces%20a%20research%20agreement,across%20dozens%20of%20genetic%20diseases.">
 Sanofi
 </a>
 (April 2016) to repurpose Sanofi&rsquo;s clinical-stage molecules
 
 
 In June 2021, the company entered into a collaboration with the Montreal-based Mila - Quebec Artificial Intelligence (AI) Institute, to leverage its network of expert scientists and professionals to accelerate the company&rsquo;s machine learning capabilities. The company also announced it will launch its first major multidisciplinary expansion, in Toronto, to further enhance tech-enabled drug discovery, by the end of 2021.&nbsp;
 
 
 Funding and financials
 
 
 Recursion secured a USD 50 million investment from NVIDIA in July 2023 in the form of a private investment in public equity (PIPE) to develop its AI foundation models for biology and chemistry. The funding was linked to its NVIDIA partnership mentioned above.
 
 
 The company&rsquo;s revenue in 2023 amounted to USD 44.6 million as opposed to USD 39.8 million in 2022.&nbsp;
 
</div>

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Vori Health is a virtual and in-person musculoskeletal (MSK) therapy provider, offering personalized care plans.The company provides chronic care management services such as physical therapy, health coaching, and nutritional guidance. Members can schedule virtual and in-person visits, contact a health coach, receive at-home physical therapy exercises, and track their progress via Vori’s mobile app. The platform also provides a social network, group classes, educational content, community forums, blogging, live messaging and immersive care.Key customers and partnershipsIn <a href="https://sp-edge.com/updates/24793">December 2023</a>, the company partnered with Contigo Health to discover MSK benefit solutions for self-funded employers.&nbsp;Funding and financialsIn <a href="https://sp-edge.com/updates/4101">July 2021,</a> Vori Health raised a total of USD 50 million in a Series A funding round. The company used the proceeds to further develop its MSK platform and expand its service offering across the US.

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

<div>
 
 California-based Transcarent provides a wide spectrum of 24/7 virtual care services, such as urgent care, lower-cost medications, behavioral health, at-home care, and second opinion consultations. Members can connect with doctors and obtain other medical services via Transcarent&rsquo;s mobile app. As of January 2022, the company had more than 80 self-insured employers. 
 
 
 In May 2022, the company 
 <a href="https://sp-edge.com/updates/10597">
 launched a behavioral health offering
 </a>
 for self-insured corporates, employees, and their families. 
 
 
 In September 2022, the company 
 <a href="https://sp-edge.com/updates/13153">
 launched a pharmacy benefit offering
 </a>
 for self-insured employers.
 
 
 In March 2023, the company 
 <a href="https://sp-edge.com/updates/16876">
 announced plans to acquire the virtual care platform and care offering of fellow virtual care provider 98point6
 </a>
 in a deal worth USD 100 million. The acquisition announcement noted 98point6&rsquo;s self-insured employer business, affiliated physician groups, and a software license will be acquired. The deal is expected to close by late March 2023.
 
 
 
 
 Key customers and partnerships
 
 
 In September 2023, the company 
 <a href="https://sp-edge.com/updates/22202">
 launched its National Independent Provider Ecosystem
 </a>
 which aims to provide national employers and their employees with easy access to high-quality, affordable healthcare. 
 As a part of the offering, Transcarent has partnered with 10 health systems across the US to offer patients a connected member experience, high-quality outcomes, and predictable, lower costs of care.
 
 
 In November 2022, the company 
 <a href="https://sp-edge.com/updates/14258">
 partnered with Prescryptive Health
 </a>
 to launch its pharmacy benefit solution, &ldquo;Transcarent Pharmacy Care.&rdquo; The solution allows Transcarent members to access Prescryptive Health&rsquo;s network of over 60,000 pharmacies. Members are able to use digital prescriptions, compare prices, and choose a pharmacy to fill out prescriptions or deliver the drugs home.
 
 
 In January 2023, the company 
 <a href="https://sp-edge.com/updates/15695">
 partnered with Cleveland Clinic
 </a>
 to provide specialist second opinion consults to Transcarent&rsquo;s members. Through the partnership, Transcarent members are able to consult with Cleveland Clinic&rsquo;s 3,500 expert specialists, with over 550 subspecialties, for second opinions as part of Transcarent&rsquo;s benefits with no out-of-pocket expenses in some cases.
 
 
 In June 2023, the company 
 <a href="https://sp-edge.com/updates/19425">
 partnered with virtual orthopedic and musculoskeletal platform ViewFi
 </a>
 to offer users orthopedic and musculoskeletal care via Transcarent&rsquo;s platform. Through the partnership, ViewFi will provide care services for Transcarent&rsquo;s Orthopedic Consult Solution, allowing patients to gain access to a virtual diagnostic team of orthopedic specialists and musculoskeletal-related physical therapy and pain management. These services will be accessible via Transcarent&rsquo;s app, with ViewFi acting as a digital front door.
 
 
 Funding and financials
 
 
 The company received its most recent injection of investment in January 2022, when it raised USD 200 million in a Series C funding round, which propelled it to unicorn status at a USD 1.62 billion valuation. The funds were allocated for its R&amp;D programs as well as scaling up its team, and entering into new markets including Medicare Advantage. 
 
 
 
</div>

Enabling the health systems to seamlessly connect, exchange, and interpret shared data

Hospital Interoperability

<div>
 
 Redox connects healthcare software solutions to healthcare providers using a single API for exchanging healthcare data. It standardizes healthcare data from EHR vendors.
 
</div>

Longevity Tech

<div>
 
 Recursion Pharmaceuticals is a biotech company that combines experimental biology and AI to identify treatments for rare diseases, aging, inflammation, infectious diseases, and immunology. The company's therapeutic areas focus on oncology and rare and other.&nbsp;
 
 
 
 
 Its integrated recursion operating system creates a closed-loop system, combining proprietary in-house data generation and advanced computational tools to generate novel insights to initiate or accelerate therapeutic programs. Recursion has already mapped out over three trillion searchable gene and compound relationships, which is intended to allow a better comprehension of biology and chemistry and how they interact, to help scientists navigate their way to new drugs more efficiently.
 
 
 
 
 Treatments are initially developed &ldquo;in silico,&rdquo; meaning within computer software, by simulating how many thousands of potential drug candidates would interact with millions of disease models to understand compounds with interesting reactions. As of May 2023, the company reported that its labs were able to perform up to 2.2 million such experiments a week.
 
 
 
 
 Key customers and partnerships
 
 
 
 -Recursion Pharmaceuticals entered a multi-year, strategic collaboration with Bayer (biotech and pharmaceutical company) in the area of fibrosis in August 2020. Under this partnership, the companies expect to initiate over a dozen programs to identify novel therapeutics for fibrotic diseases across multiple organ systems, including lung, liver, and heart. Bayer has contributed approximately 500,000 compounds from its proprietary library.
 
 
 
 
 -In December 2021, the company entered a multi-year, strategic collaboration with Roche (global diagnostics and pharmaceuticals company) and Genentech (biotechcompany) in key areas of neuroscience and an oncology indication. Through this partnership, the company is working with Roche and Genentech's R&amp;D units to enhance Recursion OS and Maps of Biology, along with extensive single-cell perturbation screening data from the two companies. The companies expect to initiate up to 40 programs over a decade or longer.
 
 
 
 
 -In July 2023, Recursion Pharmaceuticals entered a strategic collaboration with NVIDIA, global developer of AI solutions, to accelerate the development of its AI foundation models for biology and chemistry on NVIDIA DGX Cloud. These models were intended to be optimized and commercialized for possible commercial license or release on BioNeMo, NVIDIA&rsquo;s cloud service for GenAI in drug discovery.
 
 
 
 
 Funding and financials
 
 
 
 
 Recursion Pharmaceuticals raised USD 50 million investment in the form of a private investment in public equity (PIPE) by NVIDIA. The funds were to be used for the development of its AI foundation models for biology and chemistry, which, in collaboration with NVIDIA, intended to optimize and distribute to biotech companies using NVIDIA cloud services.
 
 
 
 
 The company&rsquo;s revenue in 2022 amounted to USD 39.8 million as opposed to USD 10.2 million in 2021. It made a net loss of USD 239.5 million compared to the net loss of USD 186.5 million made in the preceding year.
 
 
 
 
 
</div>

Foodsmart is a digital nutrition platform that uses personalized dietary recommendations to improve health outcomes. Foodsmart formerly Zipongo. In conjunction with the healthy food marketplace, the telenutrition program makes healthy eating personalized, convenient, and affordable.

CTRL Therapeutics operates a biotechnology company that researches on cell therapy development and treatment. It is based in Toronto, Canada.

Tepeyac Community Health Center is a non-profit community health center in Denver that has been providing care to the medically underserved.

Transcarent is a consumer-directed health and care platform for employees of self-insured employers and their families. Using a combination of software, technology, health guides, and data science, the company helps consumers with unbiased information, trusted guidance, and access to high-value care.

Vori Health offers a new care delivery model for treating musculoskeletal conditions. Its nationwide, all-inclusive medical practice is evidence-based and uniquely positioned to address a multitude of back, neck, and other joint issues. The organization offers integrated medical and rehabilitation care, physical therapy, prescriptions, imaging and lab ordering, health coaching, nutritional guidance, community support and premium instructional content. Using a unique, virtual-first care model to help patients find the best path forward, Vori Health connects patients to a trained care team that includes a board-certified, non-operative physical medicine physician, a health coach navigator, and a physical therapist who collaboratively manage the initial patient assessment and coordinate all aspects of care. Learn more at www.vorihealth.com. The company was founded in 2020 and is headquartered in New York, NY.

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to our mission is the Recursion Operating System, or Recursion OS, that combines an advanced infrastructure layer to generate what we believe is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that we use to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate our programs. We are a biotechnology company scaling more like a technology company.

Velano Vascular is a medical device innovator committed to reducing the pain, risk and inefficiencies of traditional blood collection practices while enhancing the clinical domain of vascular access. The company’s revolutionary FDA-approved PIVO device expands the use of peripheral IV lines for frequent, high quality blood draws, aiming to deliver painless, compassionate care for hospital inpatients, a safer practice for caregivers, and a more financially responsible alternative for health systems. More information is available at www.velanovascular.com.

Redox accelerates the development and distribution of healthcare software solutions with a full-service integration platform to securely and efficiently exchange data. Healthcare delivery organizations and technology vendors connect once and authorize the data they send and receive across the most extensive interoperable network in healthcare. Redox exists to make healthcare data useful and every patient experience a little bit better. It keeps patients at the forefront by helping vendors and providers integrate securely, easily, and at a reduced cost. It was founded in 2014 and is headquartered in Madison, Wisconsin.

Zebra Medical Vision’s imaging analytics platform allows healthcare institutions to identify patients at risk of disease and offer improved preventative treatment pathways to advance patient care. The company is funded by Khosla Ventures, Marc Benioff, Intermountain Investment Fund, OurCrowd Qure, Aurum, aMoon, Nvidia, J&J, and Dolby Ventures. Zebra Medical Vision has raised $52 million in funding to date and was named a Fast Company Top-5 AI and Machine Learning company. Zebra-Med leads the way in AI FDA cleared products, and is installed in hospitals globally, from Australia to India, Europe to the U.S, and the LATAM region.

R1 RCM serves as a revenue cycle management partner for hospitals and healthcare systems regardless of the payment models, patient engagement strategies, or settings of care. The company uses a proven operating model based on the R1 Performance StackSM designed to fit seamlessly into any healthcare organization’s infrastructure and to enhance the patient experience, improve provider economics, and provide revenue predictability. R1 RCM was founded on 2003 and is based in Chicago, Illinois.

Securely stream patient photographs and wound analysis directly to your desktop!  You can now objectively and automatically measure things like chronic wounds, burns, and skin conditions using only a smartphone. Nurses can stream photographs directly to your desktop, where you can evaluate, track, and manage your patients on Their secure web portal.

Empiric Health is a technology-enabled service platform that lowers cost and improves outcomes for health system customers through data-driven physician practice change. Empiric differentiates with a proprietary comparative analytics methodology and proven ability to change physician behavior, so that care providers can understand and optimize for high value, episodic care.

Tute Genomics is a cloud-based clinical genome interpretation platform that enables researchers and clinicians to utilize human genome data for scientific discovery and individualized treatment. It has developed the most advanced analytical methods for genome analysis by incorporating proprietary machine-learning algorithms into a cloud-based application that allows researchers to analyze and interpret entire human genomes and discover genes and biomarkers at an unprecedented rate.  It was founded in 2012 and headquartered in Provo, Utah.

VisitPay develops patient-centered self-pay solutions for health care providers. The company specializes in developing reports within revenue cycle management practice area, as well as enables users to merge financial, operational, and clinical information in a common reporting structure. It offers Self-Pay Engine, which provides an integrated suite of services, business intelligence, processes, and payment-producing products that allow hospitals to manage self-pay receivables. In addition, the company offers professional consulting, technology, and advisory services for self-pay management practices and systems that include dashboards and reporting tools, self-pay strategy assessment, data integration, and portfolio valuation services. Further, it provides self-pay process management services, including inventory management, work flow and processes, payment estimation, charity care identification, analytics, vendor management, payment tools and strategies, and legal programs. The company was incorporated in 2010 and is based in Boise, Idaho.

Ingram Medical offers a full range of diabetes testing supplies. Now you can get the quality testing supplies you need, at prices you can afford, delivered right to your home. Serving diabetics for over 15 years.  When you submit your information to Ingram Medical by clicking on the FREE METER* icon on our Facebook home page, a Diabetic Benefits Specialist will contact you directly. After collecting some basic information, they will find a medical supplier that best fits your personal needs. You’ll soon be saving time and money on your diabetic testing supplies by receiving reduced costs on your out-of-pocket expenses and having your supplies shipped right to your door.

Intermountain Healthcare is a nonprofit health system based in Salt Lake City, Utah, with 22 hospitals, ​about 1,100 employed primary care and secondary care physicians at more than 185 clinics in the Intermountain Medical Group, a broad range of clinics and services, and health insurance plans from SelectHealth. They are the largest healthcare provider in the Intermountain West, with over 33,000 employees and serving the healthcare needs of Utah and southeastern Idaho residents. Their mission is excellence in the provision of healthcare services to communities in the Intermountain region.

Intermountain Healthcare

Company Brief

Funding

Investors

Portfolio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless